Health Care • Medicinal Chemicals and Botanical Products
$208.79 ▲ +0.29
(+0.14%)
MKT CAP: $324.98B • VOL: 4.59M
52W L $142 52W H $214
PM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $40.65B | $37.88B | $35.17B |
| YoY Revenue Growth % | +7.3% | +7.7% | — |
| Gross Profit | $27.28B | $24.55B | — |
| Gross Margin % | 67.1% | 64.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $14.89B | $13.40B | $11.56B |
| Operating Margin % | 36.6% | 35.4% | 32.9% |
| Net Income (GAAP) | $11.35B | $7.06B | $7.81B |
| EBITDA (Normalized) | $16.15B | $14.56B | $12.82B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $12.23B | $12.22B | $9.20B |
| Capital Expenditures (CapEx) | $1.57B | $1.44B | $1.58B |
| Free Cash Flow (FCF) | $10.66B | $10.77B | $7.62B |
| FCF Margin % | 26.2% | 28.4% | 21.7% |
| Return on Invested Capital (ROIC %) | 59.2% | 65.0% | 8.5% |
| Cash & Short-Term Equivalents | $4.87B | $4.22B | — |
| Total Debt (Short + Long Term) | $34.75B | $32.24B | $41.82B |
| Total Stockholders' Equity | -$9.99B | -$11.75B | $85.79B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PM.